Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.


TSXV:TLT - Post by User

Comment by stocksnbonds458on Jun 13, 2023 10:25am
239 Views
Post# 35493512

RE:Interview about positive interim results from Phase II BCS

RE:Interview about positive interim results from Phase II BCS Thanks for the link, an amazing interview! This is much more than just promising, as it proves the science behind TLT's is a winner. Roger stated that they will wait until the completion of the phase 2 trial (100 patients) prior to submitting to the FDA for commercial approval (possible mid 2024 ?). This puts us at least a year away from an appreciable increase in stare price, not sure if BTD is still on the table after watching this interview. If it is, BTD will create a small pop in share price, but nowhere near where most longs would be willing to sell at. For that payday we will be patiently waiting at least another year by the looks of it. I'm okay to wait
<< Previous
Bullboard Posts
Next >>